Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Emerge Weight Loss vs NowPatient

Emerge Weight Loss
Graded #447

Lower grade

vs+10.399999999999999
NowPatient
Graded #217

Higher grade

The verdict

NowPatient takes it — 65.5/100 to 55.1/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmerge Weight Loss +1
36
35
Dose & formulationNowPatient +51
42
93
Clinical oversightNowPatient +2
84
86
Labs & monitoringEven
54
54
FulfillmentEven
70
70
Contract termsEven
55
55
Emerge Weight Loss · left barNowPatient · right bar

The numbers

MetricEmerge Weight LossNowPatient
WeighScore55.1/10065.5/100
GradeCC
Scorecard rank#447#217
SemaglutideNot disclosed$1,349/mo (brand Wegovy)
Tirzepatide$287/mo (2.5 mg dose, compounded)$1,069/mo (brand Mounjaro, promotional rate)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Emerge Weight Loss

Graded #447 · C

Strengths

  • Tirzepatide-focused (largest effect-size compounded GLP-1)
  • Wide dose range available
  • Physician-supervised telemedicine model

Where it loses points

  • Semaglutide is available only on request — the site and default plans are tirzepatide-only
  • Less brand recognition than Henry Meds, Mochi, or SkinnyRx
NowPatient

Graded #217 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard